Understand the source comparison
Best Peptides for Low Growth Hormone: Research Comparison
| Peptide | Mechanism | Half-Life | Typical Research Dose | IGF-1 Elevation (%) | Synergy Potential | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH receptor agonist | 6–8 days | 30–60 mcg/kg weekly | 60–80% | High with GHRPs | Best for sus
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Mechanism | Half-Life | Typical Research Dose | IGF-1 Elevation (%) | Synergy Potential | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 (with DAC) | GHRH receptor agonist | 6–8 days | 30–60 mcg/kg weekly | 60–80% | High with GHRPs | Best for sustained elevation with minimal injection frequency. Ideal when stable IGF-1 baseline is the research goal || Ipamorelin | Ghrelin receptor agonist (GHSR1a) | ~2 hours | 200–300 mcg 2–3×/day | 40–60% (acute pulse) | High with GHRH analogs | Best for pulsatile restoration without cortisol elevation. Preferred GHRP for chronic protocols due to no tachyphylaxis || Hexarelin | Ghrelin receptor agonist (GHSR1a + CD36) | ~70 minutes | 100 mcg 2–3×/day | 80–120% (acute pulse) | High but short-term only | Highest acute GH peaks but receptor desensitization limits use to 4–6 weeks. Best for short-cycle injury recovery models || MK-677 | Non-peptide GH secretagogue (oral) | ~24 hours | 10–25 mg/day oral | 40–60% | Minimal (saturates GHSR1a) |